Soliris access in the United Arab Emirates: the EDE named-patient pathway

Last reviewed 2026-05-12 by the Reserve Meds clinical and regulatory team. This page combines the UAE country research module with the Soliris drug module to describe the path families actually walk.

Quick orientation

Soliris (eculizumab) is a humanized IgG2/4 kappa monoclonal antibody that blocks cleavage of the terminal complement protein C5. The FDA first approved Soliris on 16 March 2007 for paroxysmal nocturnal hemoglobinuria (PNH), with subsequent expansions for atypical hemolytic uremic syndrome (aHUS, 2011), anti-AChR antibody-positive generalized myasthenia gravis (gMG, 2017), and anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD, 2019). Soliris is manufactured by Alexion Pharmaceuticals, AstraZeneca's rare-disease division since 2021. Soliris is registered with the UAE Ministry of Health and Prevention, generally for PNH and aHUS, with availability concentrated at tertiary hospitals and specialty infusion centers. Reserved for you.

Why UAE patients need Soliris via a named-patient pathway

The UAE access gap for Soliris is a stocking and indication gap, not a registration gap for PNH or aHUS. Three patterns recur. First, registered but concentrated. Soliris is registered in the UAE but stocking is concentrated at one or two tertiary infusion centers, and patients living outside those catchment areas cannot access continuous supply through their local hospital pharmacy. Second, registered for one indication, prescribed for another. Soliris is generally registered locally for PNH and aHUS; patients with gMG or NMOSD who are clinically appropriate for eculizumab face an off-label-in-country situation even though the FDA-approved indication is on-label internationally. Third, cost denial without coverage. Even where Soliris is technically available, the absence of insurer coverage for terminal complement inhibitors in the patient's specific indication, or the absence of any reimbursement at all for non-citizen residents, forces a cash-pay procurement pathway. The international biosimilar landscape is also in transition; biosimilar eculizumab (EPYSQLI, Bkemv) launched in the US in 2024 to 2025 but is not yet registered in the UAE, so the US-side procurement remains anchored to branded Soliris for UAE-bound shipments unless biosimilar is specifically requested and clinically appropriate.

Reserve Meds operates squarely in this segment: cash-pay UAE patients without payer coverage for terminal complement inhibitors, who need a single coordinator to handle quote, US procurement, cold-chain logistics, infusion-site delivery, and the local pharmacovigilance handshake.

The EDE named-patient pathway applied to Soliris

The federal pathway for a UAE-licensed physician to obtain a medicine that is not registered for the patient's indication, or not stocked locally, is the unregistered-medicine import permit, administered through the Emirates Drug Establishment (EDE) portal at ede.gov.ae since 29 December 2025, when the EDE took over 44 core services from MOHAP under Federal Decree-Law No. 38 of 2024. For Soliris, the EDE filing typically supports one of three scenarios: a PNH or aHUS case where local supply cannot meet the every-14-day maintenance cadence, a gMG or NMOSD case where the FDA-approved indication is on-label internationally but the locally registered indication set is narrower, or a continuity-of-supply case for a patient transitioning from a US prescriber to UAE follow-up care.

The clinical justification letter is structured around the patient's specific indication. For PNH, the diagnosis is established by flow cytometry confirmation of PNH clone size, with documented intravascular hemolysis (LDH, reticulocyte count, indirect bilirubin) and clinical features. For aHUS, the diagnosis is the complement-mediated thrombotic microangiopathy presentation, supported by genetic testing where available, with platelet count, serum creatinine, and LDH documented. For gMG, anti-AChR antibody positivity and the clinical pattern of refractory generalized disease are established. For NMOSD, anti-AQP4 antibody positivity and the relapse history are established. In all cases, the meningococcal vaccination status is documented and the REMS-equivalent counselling record sits in the file.

A complete EDE application typically includes the clinical justification letter from the treating hematologist, nephrologist, neurologist, or rheumatologist (depending on indication), the treating physician's UAE licence (MOHAP, DHA, DOH, or Sharjah Health Authority depending on practice location), the meningococcal vaccination record (serogroups A, C, W, Y, and B, completed at least two weeks before the first dose), an anonymised patient identifier, full product details (30 mL single-use vials at 10 mg per mL, 300 mg per vial; vial count for the induction phase and the first maintenance window), the destination infusion site name and pharmaceutical establishment licence, the cold-chain handling plan (2 to 8 degrees Celsius, do not freeze, do not shake, protect from light), and the dose schedule. Approval timelines for routine cases are 5 to 15 business days.

Where Soliris gets dispensed in the UAE

Soliris is administered as an intravenous infusion at a UAE-licensed infusion center. The infusion site, not the patient's home, is the delivery endpoint. Within the UAE, the candidate facilities for adult Soliris infusion include Cleveland Clinic Abu Dhabi (multispecialty including hematology and neurology, ASHP-accredited pharmacy), Sheikh Khalifa Medical City in Abu Dhabi (SEHA, managed by the Cleveland Clinic, cardiology, oncology, pediatric subspecialty), Tawam Hospital in Al Ain (SEHA, hematology and oncology), American Hospital Dubai (Mayo Clinic Care Network member, oncology, hematology, neurology), King's College Hospital London Dubai (UK-affiliated, strength in neurology and endocrinology), Mediclinic City Hospital in Dubai Healthcare City (oncology, urologic oncology, women's health), and NMC Healthcare flagship sites across Abu Dhabi, Dubai, Sharjah, and Al Ain. The dispensing facility holds the pharmaceutical establishment licence; smaller hospitals route Soliris cases through a Dubai or Abu Dhabi specialty importer that files the EDE application and delivers to the prescribing facility's outpatient pharmacy under chain-of-custody documentation.

The cold-chain class is standard refrigerated (2 to 8 degrees Celsius); validated qualified shippers with continuous temperature monitoring, lane-tested transit routes, and pre-clearance through UAE customs are standard. The diluted solution is stable for up to 24 hours under refrigeration or room temperature per the FDA label.

Real cost picture for Soliris in the UAE

Soliris is one of the most expensive long-running biologics in the world. Published US pricing references put the annual wholesale acquisition cost in the range of USD 500,000 to USD 700,000 for an average-weight adult, with aHUS, gMG, and NMOSD maintenance dosing landing at the higher end of the range because of the larger 1,200 mg maintenance dose. Vial-level WAC is commonly cited at approximately USD 7,000 per 300 mg vial. At the 3.67 AED to USD peg, annual cost in AED is approximately AED 1.8 million to AED 2.6 million per patient per year.

International logistics for a cold-chain biologic to the UAE typically runs in the USD 400 to 1,500 range per shipment (approximately AED 1,500 to 5,500). UAE customs and EDE permit fees are nominal relative to the drug cost. Procedural infusion costs at the dispensing center vary by institution. Insurance handling is case by case. Daman, GIG Gulf, Sukoon, ADNIC, Orient, and Thiqa each evaluate Soliris cases individually; some reimburse in full when the drug is on the patient's formulary and the indication aligns, others apply percentage reimbursement, and several require pre-authorisation. Thiqa, the government-funded programme for UAE nationals administered by Daman, has the broadest specialty coverage in Abu Dhabi. We do not promise coverage. We supply the documentation set that lets the insurer assess the case.

Typical timeline for Soliris in the UAE

For a first cycle, the inquiry-to-first-dose timeline typically runs three to six weeks. The meningococcal vaccination window is the structural floor: the FDA prescribing standard requires vaccination against serogroups A, C, W, Y, and B at least two weeks before the first dose, so any patient who is not already vaccinated has a two-week clock starting at vaccination. The EDE permit processes in 5 to 15 business days for routine cases. US-side procurement and refrigerated air freight run several days. Customs clearance and handoff to the infusion site add days. The induction phase for PNH is 600 mg IV every 7 days for the first 4 weeks (4 doses), 900 mg at week 5, then 900 mg every 14 days as ongoing maintenance. For aHUS, gMG, and NMOSD, the induction is 900 mg weekly for 4 weeks, 1,200 mg at week 5, then 1,200 mg every 14 days. Maintenance is indefinite. Reserve Meds coordinates the every-14-day procurement so the vials are in the infusion-site pharmacy in advance of the scheduled infusion date.

What your physician needs to provide

The treating UAE specialist's clinical justification letter establishes the patient's diagnosis with the indication-specific objective markers (PNH flow cytometry; aHUS thrombotic microangiopathy picture; anti-AChR positive gMG; anti-AQP4 positive NMOSD), the prior therapy history, and the rationale for eculizumab specifically. For indications where Ultomiris (ravulizumab) is also locally available, the letter typically addresses why eculizumab rather than the every-8-week alternative (clinician judgment, transition continuity, or specific clinical considerations). The dose plan is documented at the indication-appropriate induction and maintenance schedule.

Three documents accompany the letter. The meningococcal vaccination record (serogroups A, C, W, Y, and B, completed at least two weeks before the first dose, with revaccination per ACIP guidance). The infection counselling record acknowledging serious meningococcal infection risk. The infusion site confirmation with pharmaceutical establishment licence reference. The treating physician's UAE licence (MOHAP, DHA, DOH, or Sharjah Health Authority) must be in active standing. Soliris is on the US REMS for ULTOMIRIS and SOLIRIS, which restricts US distribution to enrolled prescribers and certified pharmacies; the US REMS components are US regulatory infrastructure and do not transfer into the UAE, where the receiving prescriber operates under local pharmacovigilance rules. Reserve Meds documents the vaccination and counselling status as part of intake regardless, because the patient safety rationale travels with the patient.

Common questions about Soliris in the UAE

Will Daman, Thiqa, GIG Gulf, Sukoon, ADNIC, or Orient cover this? Each insurer assesses Soliris cases case by case. For locally registered indications (PNH, aHUS), partial or full reimbursement is sometimes available where the patient is on a formulary-supported plan. For gMG or NMOSD cases, where the local registration may not yet include the indication, coverage is less common. Pre-authorisation is the norm. We do not promise coverage.

Can a DHA-licensed or DOH-licensed specialist sign for Soliris? Yes. Any UAE-licensed specialist practicing in good standing in the emirate of the dispensing facility has signing authority. The signing specialist matches the indication: hematology for PNH, nephrology for aHUS, neurology for gMG and NMOSD.

Is Soliris a controlled substance? No. Soliris is not a DEA scheduled substance. The federal narcotics framework does not apply.

What is the meningococcal vaccination requirement? Patients must be vaccinated against meningococcal serogroups A, C, W, Y, and B at least two weeks before the first dose, with revaccination per ACIP guidance. Meningococcal infections have been reported in vaccinated and unvaccinated patients on the drug, so vaccination is necessary but not sufficient; clinical vigilance for infection signs is part of ongoing care.

Why Soliris versus Ultomiris? Ultomiris (ravulizumab) is the longer-acting C5 inhibitor from the same manufacturer, dosed every 8 weeks in maintenance rather than every 2 weeks. Soliris remains in use where Ultomiris is not yet locally registered or reimbursed, or where the treating clinician has clinical reasons to continue eculizumab specifically. The clinical choice rests with the treating team.

Can I receive Soliris at home? No. Soliris must be administered at a UAE-licensed infusion site. Home infusion is not the model for this drug.

What about discontinuation? Soliris is not curative. Discontinuation in PNH and aHUS carries a documented risk of severe hemolysis or thrombotic microangiopathy rebound. Patients planning a treatment pause require monitoring per the FDA label's warnings, and the discussion is held with the treating clinician.

Where Reserve Meds fits in Soliris cases

Reserve Meds is a US-based concierge coordinator. We do not replace the UAE treating specialist, the EDE, the infusion site, or Alexion's commercial and pharmacovigilance teams. For Soliris specifically, our work carries three operating priorities. First, the infusion site, not the patient's home, is the delivery endpoint; every Soliris quote requires a confirmed receiving infusion center in the destination country before procurement begins. Second, the meningococcal vaccination requirement is a hard prerequisite of the US prescribing standard and the patient safety rationale; we document vaccination status as part of intake even when local prescribing rules differ. Third, because Ultomiris is often the preferred therapy in markets where it is available, the patient onboarding conversation includes a clinical-context note confirming the treating physician's specific decision to continue eculizumab. We hold one named coordinator across the every-14-day cadence so the vial is in the infusion-site pharmacy in advance of each scheduled infusion. No prior Reserve Meds case experience for Soliris as of this review date; the operating playbook is documented. Reserved for you.

Next step

If a treating specialist in the UAE has identified Soliris as the right therapy for a patient with PNH, aHUS, gMG, or NMOSD, the waitlist is the first step. We respond within 24 to 48 hours with an eligibility note and a documentation kit for the physician.

Join the Soliris waitlist

Reserved for you.

Related

• Soliris clinical resource
• Fabhalta in the UAE
• Soliris in Saudi Arabia
• United Arab Emirates country page

Sources

1. FDA label, Soliris (eculizumab), Alexion Pharmaceuticals, 2025 revision. Includes the meningococcal vaccination requirement and the ULTOMIRIS and SOLIRIS REMS framework.
2. UAE Ministry of Health and Prevention, Issue of Permit to Import Medicines for Personal Use; UAE Federal Decree-Law No. 38 of 2024 and the Emirates Drug Establishment portal at ede.gov.ae.
3. Drugs.com Soliris pricing guide; annual WAC range USD 500,000 to USD 700,000 depending on indication and weight; ICER Final Evidence Report on Eculizumab and Efgartigimod for gMG (2021).